Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRNXNASDAQ:DAWNNASDAQ:PTGXNASDAQ:SRRK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRNXCrinetics Pharmaceuticals$31.36+2.4%$35.78$29.18▼$62.53$2.92B0.58839,301 shs442,834 shsDAWNDay One Biopharmaceuticals$7.85+3.1%$10.41$7.52▼$18.07$795.13M-1.381.10 million shs289,055 shsPTGXProtagonist Therapeutics$48.13+2.7%$42.94$24.22▼$60.60$2.95B2.34797,925 shs354,570 shsSRRKScholar Rock$31.29+4.1%$37.22$6.76▼$46.98$2.95B0.591.18 million shs611,193 shs10 Stocks Set to Soar in Spring 2025Market volatility creates opportunity. Our analysts have pinpointed 10 stocks perfectly positioned for exceptional growth this spring, even amid economic uncertainty. Don't miss your chance to access this timely research and invest with confidence.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRNXCrinetics Pharmaceuticals-8.71%-12.69%-14.42%-40.11%-34.19%DAWNDay One Biopharmaceuticals-4.04%-8.09%-16.00%-39.94%-52.91%PTGXProtagonist Therapeutics-3.06%-8.17%+24.71%+21.45%+65.77%SRRKScholar Rock-6.50%-9.68%-22.57%-30.45%+79.04%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRNXCrinetics Pharmaceuticals4.3725 of 5 stars4.52.00.03.73.32.50.0DAWNDay One Biopharmaceuticals2.8992 of 5 stars4.62.00.00.01.92.50.0PTGXProtagonist Therapeutics3.6005 of 5 stars4.51.00.00.03.42.51.3SRRKScholar Rock4.1194 of 5 stars3.50.00.04.43.53.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRNXCrinetics Pharmaceuticals 2.92Moderate Buy$73.00132.78% UpsideDAWNDay One Biopharmaceuticals 3.13Buy$32.29311.55% UpsidePTGXProtagonist Therapeutics 3.00Buy$62.5629.96% UpsideSRRKScholar Rock 3.00Buy$42.6736.38% UpsideCurrent Analyst Ratings BreakdownLatest DAWN, CRNX, SRRK, and PTGX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/28/2025PTGXProtagonist TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$70.00 ➝ $70.003/25/2025CRNXCrinetics PharmaceuticalsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$60.003/25/2025DAWNDay One BiopharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$39.00 ➝ $27.003/25/2025SRRKScholar RockWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$50.003/17/2025SRRKScholar RockWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$50.003/11/2025PTGXProtagonist TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$70.003/11/2025PTGXProtagonist TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$60.00 ➝ $76.003/11/2025PTGXProtagonist TherapeuticsBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$62.00 ➝ $72.003/10/2025PTGXProtagonist TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$54.00 ➝ $54.003/5/2025DAWNDay One BiopharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$39.00 ➝ $34.003/4/2025PTGXProtagonist TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$53.00 ➝ $57.00(Data available from 4/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRNXCrinetics Pharmaceuticals$1.04M2,808.49N/AN/A$8.07 per share3.89DAWNDay One Biopharmaceuticals$131.16M6.06N/AN/A$3.98 per share1.97PTGXProtagonist Therapeutics$434.43M6.80N/AN/A$5.84 per share8.24SRRKScholar Rock$33.19M89.24N/AN/A$3.12 per share10.03Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRNXCrinetics Pharmaceuticals-$214.53M-$3.71N/AN/AN/AN/A-36.12%-31.89%5/8/2025 (Estimated)DAWNDay One Biopharmaceuticals-$188.92M-$1.08N/AN/AN/AN/A-22.40%-19.79%5/5/2025 (Estimated)PTGXProtagonist Therapeutics-$78.96M$4.2018.05N/AN/A52.76%34.68%30.98%5/6/2025 (Estimated)SRRKScholar Rock-$165.79M-$2.45N/AN/AN/AN/A-145.60%-91.83%5/6/2025 (Estimated)Latest DAWN, CRNX, SRRK, and PTGX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/27/2025Q4 2024CRNXCrinetics Pharmaceuticals-$0.92-$0.88+$0.04-$0.88$0.73 millionN/A2/25/2025Q4 2024DAWNDay One Biopharmaceuticals-$0.35-$0.69-$0.34-$0.69$27.11 million$29.21 million2/21/2025Q4 2024PTGXProtagonist Therapeutics-$0.09$1.98+$2.07$1.98$56.65 million$170.64 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRNXCrinetics PharmaceuticalsN/AN/AN/AN/AN/ADAWNDay One BiopharmaceuticalsN/AN/AN/AN/AN/APTGXProtagonist TherapeuticsN/AN/AN/AN/AN/ASRRKScholar RockN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRNXCrinetics PharmaceuticalsN/A16.3916.38DAWNDay One BiopharmaceuticalsN/A14.6214.55PTGXProtagonist TherapeuticsN/A10.6910.70SRRKScholar Rock0.633.883.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRNXCrinetics Pharmaceuticals98.51%DAWNDay One Biopharmaceuticals87.95%PTGXProtagonist Therapeutics98.63%SRRKScholar Rock91.08%Insider OwnershipCompanyInsider OwnershipCRNXCrinetics Pharmaceuticals6.00%DAWNDay One Biopharmaceuticals8.40%PTGXProtagonist Therapeutics5.40%SRRKScholar Rock19.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRNXCrinetics Pharmaceuticals21093.05 million87.17 millionOptionableDAWNDay One Biopharmaceuticals60101.36 million92.38 millionOptionablePTGXProtagonist Therapeutics12061.38 million56.38 millionOptionableSRRKScholar Rock14094.68 million75.64 millionOptionableDAWN, CRNX, SRRK, and PTGX HeadlinesRecent News About These CompaniesCorient Private Wealth LLC Takes $394,000 Position in Scholar Rock Holding Co. (NASDAQ:SRRK)March 31 at 3:18 AM | marketbeat.comAmerican Century Companies Inc. Acquires New Holdings in Scholar Rock Holding Co. (NASDAQ:SRRK)March 30 at 3:45 AM | marketbeat.comRaymond James Financial Inc. Takes Position in Scholar Rock Holding Co. (NASDAQ:SRRK)March 30 at 3:15 AM | marketbeat.comLoomis Sayles & Co. L P Makes New Investment in Scholar Rock Holding Co. (NASDAQ:SRRK)March 29, 2025 | marketbeat.comBIT Capital GmbH Decreases Position in Scholar Rock Holding Co. (NASDAQ:SRRK)March 28, 2025 | marketbeat.comScholar Rock Announces FDA Priority Review Designation For Apitegromab - Quick FactsMarch 27, 2025 | nasdaq.comFDA accepts Scholar Rock BLA for apitegromab under priority review to treat SMAMarch 27, 2025 | markets.businessinsider.comInsider Selling: Scholar Rock Holding Co. (NASDAQ:SRRK) Insider Sells 6,500 Shares of StockMarch 26, 2025 | marketbeat.comScholar Rock (NASDAQ:SRRK) Receives "Outperform" Rating from WedbushMarch 26, 2025 | marketbeat.comSwiss National Bank Boosts Stock Position in Scholar Rock Holding Co. (NASDAQ:SRRK)March 25, 2025 | marketbeat.comVictory Capital Management Inc. Takes Position in Scholar Rock Holding Co. (NASDAQ:SRRK)March 23, 2025 | marketbeat.comAlphaQuest LLC Sells 34,414 Shares of Scholar Rock Holding Co. (NASDAQ:SRRK)March 21, 2025 | marketbeat.comScholar Rock Holding Co. (NASDAQ:SRRK) Director Katie Peng Sells 1,006 SharesMarch 20, 2025 | marketbeat.com54,717 Shares in Scholar Rock Holding Co. (NASDAQ:SRRK) Bought by Proficio Capital Partners LLCMarch 19, 2025 | marketbeat.comWedbush Reaffirms "Outperform" Rating for Scholar Rock (NASDAQ:SRRK)March 18, 2025 | marketbeat.comSkandinaviska Enskilda Banken AB publ Buys Shares of 28,599 Scholar Rock Holding Co. (NASDAQ:SRRK)March 18, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Purchases 119,616 Shares of Scholar Rock Holding Co. (NASDAQ:SRRK)March 18, 2025 | marketbeat.comTD Cowen Reaffirms Their Buy Rating on Scholar Rock Holding (SRRK)March 17, 2025 | markets.businessinsider.comScholar Rock announces Phase 3 SAPPHIRE dataMarch 16, 2025 | markets.businessinsider.comScholar Rock Presents New Phase 3 SAPPHIRE Data at the 2025 Muscular Dystrophy Association Clinical & Scientific ConferenceMarch 16, 2025 | businesswire.comScholar Rock issues equity awards to new employeesMarch 16, 2025 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDAWN, CRNX, SRRK, and PTGX Company DescriptionsCrinetics Pharmaceuticals NASDAQ:CRNX$31.36 +0.74 (+2.42%) As of 12:48 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.Day One Biopharmaceuticals NASDAQ:DAWN$7.84 +0.24 (+3.09%) As of 12:48 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.Protagonist Therapeutics NASDAQ:PTGX$48.13 +1.25 (+2.67%) As of 12:48 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.Scholar Rock NASDAQ:SRRK$31.28 +1.23 (+4.08%) As of 12:48 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Analyst Targets Signal More Growth in CrowdStrike Stock NextEra Energy Stock Sees Spike in Bullish Call Activity 2 Reasons to Buy Apple Stock and 1 Significant Risk Salesforce: The Most Resilient Software Stock for Downturns D-Wave: Multiple Use Cases Emerge Following Quantum Supremacy Boeing Stock Upgraded After Beating Lockheed for Jet Deal Amazon Falls Back to a Key Support Line: Here's How to Play It Why Howmet Could Be the Sleeper Aerospace Name of 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
